Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ONCY save search
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 9.52%
H: 10.87%
C: 8.7%
biotech financial results
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
Published: 2022-11-07 (Crawled : 13:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 9.52%
H: 10.87%
C: 8.7%
biotech meeting response results cancer study pancreatic phase 1
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting
Published: 2022-03-09 (Crawled : 13:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 8.72%
H: 1.23%
C: -1.85%
biotech phase 1b phase 1 roof iot phase 2b
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
Published: 2022-03-09 (Crawled : 13:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 8.72%
H: 1.23%
C: -1.85%
biotech pos ces presentation iot
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 6.52%
H: 6.12%
C: 5.1%
biotech cancer pancreatic
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 6.19%
H: 0.0%
C: -5.8%
biotech results
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
Published: 2021-11-05 (Crawled : 12:15) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.53%
H: 0.0%
C: -4.1%
financial results results biotech iot
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
Published: 2022-12-01 (Crawled : 13:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.11%
H: 23.24%
C: 14.59%
biotech treatment fda designation cancer pancreatic fast track designation
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Published: 2022-11-10 (Crawled : 14:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.06%
H: 6.42%
C: 4.81%
biotech meeting response cancer pancreatic
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Published: 2022-01-20 (Crawled : 14:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 4.37%
H: 6.81%
C: 3.14%
biotech america symposium gastrointestinal trial phase 1 test cancer iot enroll
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
Published: 2021-05-20 (Crawled : 13:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 4.24%
H: 5.93%
C: 3.73%
cancer biotech iot pancreatic pancreas biomarkers
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 3.95%
H: 5.7%
C: 2.53%
biotech cel preclinical cancer iot pre-clinical
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Published: 2022-03-31 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -3.66%
biotech gastrointestinal trial positive cancer phase 1
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up
Published: 2022-12-01 (Crawled : 18:00) - biospace.com/
CRBU | $3.87 -1.02% -1.03% 1.7M
|
Health Technology
|
| O: 2.47%
H: 0.0%
C: -3.98%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.11%
H: 23.24%
C: 14.59%
KTRA | $0.1204 12.95% 11.46% 7.1M
|
Distribution Services
|
| O: -1.34%
H: 57.34%
C: 34.04%
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 2.99%
H: 1.41%
C: 0.0%
fda biotech fast track designation
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.92%
H: 0.0%
C: -0.71%
biotech positive sabcs
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Published: 2024-03-07 (Crawled : 21:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.88%
H: 4.67%
C: -1.87%
biotech year financial results
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Published: 2023-06-22 (Crawled : 13:20) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.78%
H: 28.38%
C: 13.51%
trial platform
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Published: 2022-01-27 (Crawled : 12:30) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.73%
H: 0.0%
C: -5.85%
biotech chinese treatment trial cancer iot breast cancer
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
Published: 2021-04-08 (Crawled : 13:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.29%
H: 8.05%
C: 3.8%
biotech iot conference
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Published: 2022-05-04 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.16%
H: 2.11%
C: 0.7%
biotech potential cancer breast cancer biomarkers